TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8031480

Group type: EXPERIMENTAL
Intervention: Action toothbrush
Number of subjects: 56

Group type: COMPARATOR
Intervention: Oral-B toothbrush
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Both brushes
Number of subjects: 56
Study: 2691573

Group type: EXPERIMENTAL
Intervention: Clovoxamine (50 mg b.d. to 300 mg max)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Diazepam (5 mg b.d. to 30 mg max)
Number of subjects: 72
Study: 1105692

Group type: EXPERIMENTAL
Intervention: Laminaria tents inserted 14-18 hr before PGF2alpha infusion
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Laminaria tents inserted at the same time as PGF2alpha infusion
Number of subjects: 230

Group type: COMPARATOR
Intervention: Intra-amniotic PGF2alpha 40 mg
Number of subjects: 230
Study: 31836635

Group type: EXPERIMENTAL
Intervention: AM-PICC
Number of subjects: 0

Group type: COMPARATOR
Intervention: S-PICC
Number of subjects: 0
Study: 30653554

Group type: EXPERIMENTAL
Intervention: Water condition (supplementary drinking water provided throughout the day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (normal school conditions without supplementary water)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Water condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study: 28246338

Group type: EXPERIMENTAL
Intervention: Reference book providing weight‐based precalculated doses
Number of subjects: 40

Group type: COMPARATOR
Intervention: Card providing milligram‐per‐kilogram doses
Number of subjects: 40
Study: 25521275

Group type: EXPERIMENTAL
Intervention: Nerve growth factor (NGF) injection (1 µg) into tibialis anterior and erector spinae muscles and fasciae
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nerve growth factor (NGF) injection (1 µg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Acidic buffer injections (pH 4, 100 µl)
Number of subjects: 8
Study: 23142442

Group type: EXPERIMENTAL
Intervention: Rotating platform posterior stabilized total knee arthroplasty (TKA)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Kinematic subset of subjects
Number of subjects: 153
Study: 20878159

Group type: EXPERIMENTAL
Intervention: Docetaxel/cisplatin (DP) as first-line treatment
Number of subjects: 58

Group type: COMPARATOR
Intervention: FOLFIRI as first-line treatment
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: FOLFIRI as second-line treatment
Number of subjects: 58

Group type: COMPARATOR
Intervention: Docetaxel/cisplatin (DP) as second-line treatment
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Arm A (DP → FOLFIRI)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Arm B (FOLFIRI → DP)
Number of subjects: 58
Study: 19885944

Group type: EXPERIMENTAL
Intervention: Far-infrared rays (FIR) applied to three acupuncture points (Nei-Kuan (PC6), Shenmen (HT7), Sanyinjiao (SP6)) for 15 minutes twice a week for four weeks
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 70
Study: 18035955

Group type: EXPERIMENTAL
Intervention: Remifentanil 0.15 microg/kg/min
Number of subjects: 60

Group type: COMPARATOR
Intervention: Remifentanil 0.1 microg/kg/min
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (remifentanil 0.1 microg/kg/min and 0.15 microg/kg/min)
Number of subjects: 60
Study: 15277611

Group type: EXPERIMENTAL
Intervention: 10 mg donepezil daily for 12 weeks
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Open-label donepezil (5 mg daily for 6 weeks, then 10 mg daily for 6 weeks)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study: 10731625

Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 0

Group type: COMPARATOR
Intervention: D-methamphetamine
Number of subjects: 0
Study: 8923850

Group type: EXPERIMENTAL
Intervention: Acipimox (250 mg, orally)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 1404449

Group type: COMPARATOR
Intervention: Beta-carotene (0, 15, 30, 45, or 60 mg daily for approximately 9 months)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Beta-carotene (topically applied)
Number of subjects: 45
Study: 3888229

Group type: EXPERIMENTAL
Intervention: 6 g/day of fish oil (Maxepa)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 16 g/day of fish oil (Maxepa)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 25
Study: 30845754

Group type: EXPERIMENTAL
Intervention: Low fermentable, oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP)‐gluten free diet (LF‐GFD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular gluten‐free diet (R‐GFD)
Number of subjects: 0
Study: 28777139

Group type: EXPERIMENTAL
Intervention: 15-20 minutes fluid bolus
Number of subjects: 96

Group type: COMPARATOR
Intervention: 5-10 minutes fluid bolus
Number of subjects: 96
Study: 25248816

Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin (dual therapy)
Number of subjects: 574

Group type: COMPARATOR
Intervention: Aspirin alone (monotherapy)
Number of subjects: 574
Study: 23317474

Group type: EXPERIMENTAL
Intervention: Body Psychotherapy (BPT)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Pilates (active control)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Primary outcome
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness assessment
Number of subjects: 256
Study: 20927557

Group type: EXPERIMENTAL
Intervention: Minimally invasive transforaminal lumbar interbody fusion (MiTLIF)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Open transforaminal lumbar interbody fusion (OTLIF)
Number of subjects: 52
Study: 18854801

Group type: EXPERIMENTAL
Intervention: Natural plant extracts for intimate hygiene (Salvia officinalis, Camomilla recutita, Thymus vulgaris) used once or twice a day for four weeks
Number of subjects: 2641
Study: 16317014

Group type: EXPERIMENTAL
Intervention: Early chemotherapy (MVP regimen: mitomycin C 8 mg/m2, vinblastine 6 mg/m2, cisplatin 50 mg/m2 or carboplatin AUC 5) every 3 weeks for up to six cycles
Number of subjects: 43

Group type: COMPARATOR
Intervention: Delayed chemotherapy (initial best supportive care with chemotherapy added at time of symptomatic progression)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Early chemotherapy (MVP regimen)
Number of subjects: 43
Study: 14528069

Group type: EXPERIMENTAL
Intervention: Dexamethasone (Dex)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF)
Number of subjects: 28

Group type: COMPARATOR
Intervention: No pretreatment
Number of subjects: 28
Study: 10321372

Group type: EXPERIMENTAL
Intervention: Screening (chest x-ray examination and sputum cytology every four months for six years)
Number of subjects: 9211

Group type: COMPARATOR
Intervention: Usual care (annual chest x-ray examination and sputum cytology)
Number of subjects: 9211

Group type: EXPERIMENTAL
Intervention: Screening
Number of subjects: 9211
Study: 8607237

Group type: EXPERIMENTAL
Intervention: Prostate-specific antigen (PSA) measurement and digital rectal examination (DRE) followed by transrectal ultrasonography of the prostate when PSA or DRE is abnormal
Number of subjects: 14554

Group type: EXPERIMENTAL
Intervention: Annual screening with PSA
Number of subjects: 14554
Study: 1750604

Group type: EXPERIMENTAL
Intervention: Inhaled nebulised fentanyl at 318 micrograms/ml
Number of subjects: 30

Group type: COMPARATOR
Intervention: Inhaled nebulised fentanyl at 159 micrograms/ml
Number of subjects: 30

Group type: COMPARATOR
Intervention: Inhaled nebulised fentanyl at 64 micrograms/ml
Number of subjects: 30
Study: 7128188

Group type: EXPERIMENTAL
Intervention: Bromocriptine (15 mg per day)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Imipramine (75 mg per day)
Number of subjects: 9
Study: 31170926

Group type: EXPERIMENTAL
Intervention: 90° rotation technique
Number of subjects: 129

Group type: COMPARATOR
Intervention: Standard technique
Number of subjects: 129
Study: 28760278

Group type: EXPERIMENTAL
Intervention: Individualized interventions based on Q methodology
Number of subjects: 160

Group type: COMPARATOR
Intervention: Routine treatment (Control)
Number of subjects: 160
Study: 25581062

Group type: EXPERIMENTAL
Intervention: Zambia's Child Grant Program (unconditional cash transfers)
Number of subjects: 0
Study: 24416797

Group type: EXPERIMENTAL
Intervention: Pain offset (after experiencing acute physical pain)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pain offset
Number of subjects: 0
Study: 22587432

Group type: EXPERIMENTAL
Intervention: Access to hand hygiene facilities with short repetitive instruction in hand hygiene every 2 months
Number of subjects: 773

Group type: COMPARATOR
Intervention: Access to hand hygiene facilities only
Number of subjects: 773
Study: 19488607

Group type: EXPERIMENTAL
Intervention: Metformin (850 mg bid for 90 days)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 17998024

Group type: EXPERIMENTAL
Intervention: Milk beverage
Number of subjects: 10

Group type: COMPARATOR
Intervention: Fruit-flavored beverage
Number of subjects: 10
Study: 15832031

Group type: EXPERIMENTAL
Intervention: 5 mg of donepezil for 12 months
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Presence of hypertension (HBP) and periventricular hyperintensities (PVH)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 50
Study: 12210644

Group type: EXPERIMENTAL
Intervention: Anorexia nervosa (AN)
Number of subjects: 4185

Group type: EXPERIMENTAL
Intervention: Bulimia nervosa (BN)
Number of subjects: 4185

Group type: EXPERIMENTAL
Intervention: Eating disorders not otherwise specified (EDNOS)
Number of subjects: 4185
Study: 10323086

Group type: EXPERIMENTAL
Intervention: IgAN
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: SHN
Number of subjects: 27
Study: 9846856

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg Zn as ZnSO4 daily in fruit juice, Monday to Friday for 6 months)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study: 1679448

Group type: EXPERIMENTAL
Intervention: Hibiscrub
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Surgiscrub
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Uniscrub
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Macrocide
Number of subjects: 73
Study: 6351148

Group type: EXPERIMENTAL
Intervention: Biofeedback Group (EMG and thermal biofeedback with relaxation strategies)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Waiting List Control Group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Benson's Relaxation Response procedure
Number of subjects: 30
Study: 29363437

Group type: EXPERIMENTAL
Intervention: Full presentation of automated procedural guidance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Step-by-step presentation of automated procedural guidance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study: 25918755

Group type: EXPERIMENTAL
Intervention: AV eyeglasses
Number of subjects: 49

Group type: COMPARATOR
Intervention: No AV eyeglasses
Number of subjects: 49
Study: 24041436

Group type: EXPERIMENTAL
Intervention: Computer-based interactive simulation
Number of subjects: 44

Group type: COMPARATOR
Intervention: High-fidelity hands-on simulation
Number of subjects: 44
Study: 21196669

Group type: EXPERIMENTAL
Intervention: Ketamine (1mg/kg intravenously at induction of anesthesia)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (saline, equal volume to ketamine)
Number of subjects: 80
Study: 18538192

Group type: EXPERIMENTAL
Intervention: Management of nonsustained ventricular tachycardia in patients with dilated cardiomyopathy
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Management of nonsustained ventricular tachycardia in patients with hypertrophic cardiomyopathy
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Management of nonsustained ventricular tachycardia in patients after myocardial infarction
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Data from ICD trials in older patients
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Management of recurrent ventricular arrhythmias in a patient with an ICD
Number of subjects: 5
Study: 16823727

Group type: EXPERIMENTAL
Intervention: Insulin glulisine
Number of subjects: 59

Group type: COMPARATOR
Intervention: Insulin as part
Number of subjects: 59
Study: 14641967

Group type: EXPERIMENTAL
Intervention: Ferrous fumarate with ascorbic acid (4:1 molar ratio)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Ferrous fumarate
Number of subjects: 10

Group type: COMPARATOR
Intervention: Ferrous fumarate with Na2EDTA (1:1 molar ratio)
Number of subjects: 10

Group type: COMPARATOR
Intervention: FeSO4
Number of subjects: 10
Study: 10688392

Group type: EXPERIMENTAL
Intervention: Penciclovir cream
Number of subjects: 541

Group type: COMPARATOR
Intervention: Purified water (control)
Number of subjects: 541
Study: 8839906

Group type: EXPERIMENTAL
Intervention: 5 mg tropisetron
Number of subjects: 152

Group type: COMPARATOR
Intervention: 2 mg tropisetron
Number of subjects: 152
Study: 1500686

Group type: EXPERIMENTAL
Intervention: human lymphoblastoid interferon (ly‐IFN) at a dose of 5 MU/m2 i.m. three times a week for 6 months
Number of subjects: 18

Group type: COMPARATOR
Intervention: no treatment
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: human lymphoblastoid interferon (ly‐IFN)
Number of subjects: 18
Study: 6391415

Group type: EXPERIMENTAL
Intervention: Functional bracing in supination (FUSU)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Dorsal plaster immobilization (DPI)
Number of subjects: 145
Study: 31272883

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Everolimus
Number of subjects: 0
Study: 30536163

Group type: COMPARATOR
Intervention: Apalutamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enzalutamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Abiraterone and prednisone
Number of subjects: 0
Study: 27548898

Group type: EXPERIMENTAL
Intervention: Problem Solving Treatment (PST)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Referral to physician
Number of subjects: 85

Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 85
Study: 24268105

Group type: COMPARATOR
Intervention: Medical management alone
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Medical management with interventional therapy
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Interventional therapy
Number of subjects: 223
Study: 22548767

Group type: COMPARATOR
Intervention: Omeprazole (10 mg once daily)
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Famotidine (10 mg twice daily)
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Mosapride (5 mg three times daily)
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: Teprenone (50 mg three times daily)
Number of subjects: 454
Study: 19918198

Group type: EXPERIMENTAL
Intervention: Soft-layered long spineboard
Number of subjects: 30

Group type: COMPARATOR
Intervention: Rigid long spineboard
Number of subjects: 30

Group type: COMPARATOR
Intervention: Vacuum mattress
Number of subjects: 30
Study: 17274349

Group type: EXPERIMENTAL
Intervention: Continuous intervention group (monthly educational campaign)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Seasonal intervention group (massive educational campaign before winters)
Number of subjects: 16
Study: 16197821

Group type: EXPERIMENTAL
Intervention: Intra-arterial thrombolysis (IAT) using urokinase
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: New techniques including sonothrombolysis, angiojet aspiration, and laser recanalization
Number of subjects: 350

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 350
Study: 12193148

Group type: EXPERIMENTAL
Intervention: Palm oil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Safflower oil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fish/safflower oil
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Olive oil
Number of subjects: 0
Study: 10388371

Group type: EXPERIMENTAL
Intervention: SMFP dentifrice containing CaCl2
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: SMFP dentifrice
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 9054246

Group type: EXPERIMENTAL
Intervention: Epidural clonidine 2 micrograms/kg followed by 0.5 microgram.kg‐1.h‐1 (group 1)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Epidural clonidine 4 micrograms/kg followed by 1 microgram.kg‐1.h‐1 (group 2)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Epidural clonidine 8 micrograms/kg followed by 2 micrograms.kg‐1.h‐1 (group 3)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Epidural clonidine 2 micrograms/kg (group 1)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Epidural clonidine 4 micrograms/kg (group 2)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Epidural clonidine 8 micrograms/kg (group 3)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Epidural clonidine (all groups)
Number of subjects: 50
Study: 2523965

Group type: EXPERIMENTAL
Intervention: Zinc gluconate
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 1020047

Group type: EXPERIMENTAL
Intervention: 131Cs scanning
Number of subjects: 283

Group type: COMPARATOR
Intervention: Clinical examination
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Clinical examination + 131Cs scanning
Number of subjects: 283
Study: 31260676

Group type: EXPERIMENTAL
Intervention: Melatonin (10 mg)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 27771796

Group type: EXPERIMENTAL
Intervention: Bilateral pelvic lymphadenectomy (PLND)
Number of subjects: 190

Group type: COMPARATOR
Intervention: No surgery (no-PLND)
Number of subjects: 190
Study: 26452713

Group type: EXPERIMENTAL
Intervention: 0.5 mg ranibizumab
Number of subjects: 500

Group type: COMPARATOR
Intervention: Sham treatment (initially randomized)
Number of subjects: 500
Study: 24365274

Group type: EXPERIMENTAL
Intervention: Group hypnosis
Number of subjects: 223

Group type: COMPARATOR
Intervention: Relaxation
Number of subjects: 223
Study: 22234002

Group type: EXPERIMENTAL
Intervention: On-pump CABG
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 28
Study: 19787608

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB) injection 2.5 mg 3-5 days before operation
Number of subjects: 40

Group type: COMPARATOR
Intervention: No injection before operation (noninjected group)
Number of subjects: 40
Study: 16413895

Group type: EXPERIMENTAL
Intervention: Magnification loupes
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Endoscope
Number of subjects: 59
Study: 15545877

Group type: EXPERIMENTAL
Intervention: Tc-99m-labeled antigranulocyte monoclonal antibody fragment Fab'2 (SMab, Leukoscan); 20 mCi (740 MBq) injected, scans obtained within 3 and 8 hours post-injection.
Number of subjects: 117
Study: 11727205

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IGI)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Plasmapheresis
Number of subjects: 71
Study: 9450166

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) inhalation therapy (400 micrograms/day)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no BDP inhalation therapy)
Number of subjects: 42
Study: 7954563

Group type: EXPERIMENTAL
Intervention: Group 1 (patients with rheumatic mitral valve disease in atrial fibrillation)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Group 2 (patients with rheumatic mitral valve disease in sinus rhythm)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group for group 1 (36 patients with nonrheumatic atrial fibrillation)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group for group 2 (22 patients with various cardiovascular diseases and sinus rhythm)
Number of subjects: 61
Study: 3631765

Group type: EXPERIMENTAL
Intervention: Periumbilical peritoneal lavage
Number of subjects: 53

Group type: COMPARATOR
Intervention: Infraumbilical peritoneal lavage
Number of subjects: 53
Study: 29322434

Group type: EXPERIMENTAL
Intervention: High-dose N-acetylcysteine (NAC) 100 mg/kg bolus followed by intracoronary NAC 480 mg during PCI then intravenous NAC 10 mg/kg for 12 hours
Number of subjects: 100

Group type: COMPARATOR
Intervention: 5% dextrose (control group)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: High-dose N-acetylcysteine (NAC)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: High-dose N-acetylcysteine (NAC) and control group
Number of subjects: 100
Study: 26919554

Group type: EXPERIMENTAL
Intervention: Wraparound eyeglasses in addition to medical treatment (group 1, n = 39)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Medical treatment only (group 2, n = 31)
Number of subjects: 70
Study: 24749723

Group type: EXPERIMENTAL
Intervention: Bundled intervention promoting delirium prevention, recognition, and management
Number of subjects: 19949

Group type: COMPARATOR
Intervention: Control group (aged 80 and older admitted before April 26, 2010)
Number of subjects: 19949
Study: 23141812

Group type: EXPERIMENTAL
Intervention: AMG 145 70 mg every 2 weeks
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: AMG 145 105 mg every 2 weeks
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: AMG 145 140 mg every 2 weeks
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: AMG 145 280 mg every 4 weeks
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: AMG 145 350 mg every 4 weeks
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: AMG 145 420 mg every 4 weeks
Number of subjects: 406

Group type: COMPARATOR
Intervention: Placebo every 2 weeks
Number of subjects: 406

Group type: COMPARATOR
Intervention: Placebo every 4 weeks
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg/day
Number of subjects: 406
Study: 20440092

Group type: EXPERIMENTAL
Intervention: 30 mg prednisolone administered immediately after surgery
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (no prednisolone)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Prednisolone group
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Both groups received Etorikoxib 120 mg 30 minutes before operation
Number of subjects: 78
Study: 18305291

Group type: EXPERIMENTAL
Intervention: Double-blind antidepressant treatment
Number of subjects: 24
Study: 16006206

Group type: EXPERIMENTAL
Intervention: HIV prevention program based on protection motivation theory (PMT)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 480